Global Influenzavirus B Infection Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Influenzavirus B Infection Drug Market Size and Outlook 2025-31

The global Influenzavirus B Infection Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Influenzavirus B Infection Drug Industry Forecast looks at past sales and reviews total world Influenzavirus B Infection Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Influenzavirus B Infection Drug sales for 2025 through 2031. With Influenzavirus B Infection Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Influenzavirus B Infection Drug industry. This Insight Report provides a comprehensive analysis of the global Influenzavirus B Infection Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Influenzavirus B Infection Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Influenzavirus B Infection Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Influenzavirus B Infection Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Influenzavirus B Infection Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Influenzavirus B Infection Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; APP-309 &nbsp;&nbsp;&nbsp; CF-403 &nbsp;&nbsp;&nbsp; GC-3106A &nbsp;&nbsp;&nbsp; KIN-1400 &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; AbbVie Inc &nbsp;&nbsp;&nbsp; Adimmune Corp &nbsp;&nbsp;&nbsp; Altravax Inc &nbsp;&nbsp;&nbsp; Amarillo Biosciences Inc &nbsp;&nbsp;&nbsp; Aphios Corp &nbsp;&nbsp;&nbsp; BioCryst Pharmaceuticals Inc &nbsp;&nbsp;&nbsp; Cadila Healthcare Ltd &nbsp;&nbsp;&nbsp; ContraFect Corp &nbsp;&nbsp;&nbsp; Daiichi Sankyo Company Ltd &nbsp;&nbsp;&nbsp; Fujifilm Holdings Corporation &nbsp;&nbsp;&nbsp; GlaxoSmithKline Plc &nbsp;&nbsp;&nbsp; Green Cross Corp &nbsp;&nbsp;&nbsp; Inovio Pharmaceuticals Inc &nbsp;&nbsp;&nbsp; Kineta Inc &nbsp;&nbsp;&nbsp; Medicago Inc &nbsp;&nbsp;&nbsp; MedImmune LLC &nbsp;&nbsp;&nbsp; Mucosis BV &nbsp;&nbsp;&nbsp; Novavax Inc &nbsp;&nbsp;&nbsp; Park Active Molecules &nbsp;&nbsp;&nbsp; Romark Laboratories LC &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Sanofi Pasteur SA &nbsp;&nbsp;&nbsp; Shionogi & Co Ltd &nbsp;&nbsp;&nbsp; SK Chemicals Co Ltd &nbsp;&nbsp;&nbsp; TSRL Inc &nbsp;&nbsp;&nbsp; Vaxart Inc &nbsp;&nbsp;&nbsp; Vectura Group Plc Key Questions Addressed in this Report What is the 10-year outlook for the global Influenzavirus B Infection Drug market? What factors are driving Influenzavirus B Infection Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Influenzavirus B Infection Drug market opportunities vary by end market size? How does Influenzavirus B Infection Drug break out by Type, by Application?

Report	Global Influenzavirus B Infection Drug Market Growth 2025-2031
Selected License	Multi ID: LPI23708

Buyer Information

Order Summary